Angiotensin II antagonism in clinical practice: Experience with Valsartan

Journal of Cardiovascular Pharmacology

Volumn 33, Issue SUPPL. 1, 1999, Pages

  McInnes, Gordon T ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

ACE inhibitors; Angiotensin II antagonism; Blood pressure; Trough to peak ratio; Valsartan

Indexed keywords

AMLODIPINE; ANGIOTENSIN II ANTAGONIST; ENALAPRIL; HYDROCHLOROTHIAZIDE; VALSARTAN;

ANTIHYPERTENSIVE ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; HEADACHE; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECEPTOR BLOCKING;

AGE FACTORS; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; CONTINENTAL POPULATION GROUPS; DRUG SYNERGISM; HUMANS; KIDNEY DISEASES; SEX FACTORS; TETRAZOLES; VALINE;

EID: 0032963054     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199900001-00006     Document Type: Conference Paper

References (14)

1. Messerli FH, Weber MA, Brunner HR. Angiotensin II receptor Inhibition. A new therapeutic principle. Arch Intern Med 1996; 156:1957-65.
2. 1-receptor subtype. Br J Pharmacol 1993;110:761-71.
3. 1 receptors. Regul Pept 1995;59:303-11.
4. Criscione L, Bradley WA, Bühlmayer P, et al. Valsartan: preclinical and clinical profile of an antihypertensive angiotensin-II antagonist. Cardiovasc Drug Rev 1995;13:230-50.
5. Samani NJ, Cumin F, Kelly M, Wood JM. Expression of components of the RAS during prolonged blockade at different levels in primates. Am J Physiol 1994;267:E612-9.
6. Müller P, Cohen T, de Gasparo M, Sioufi A, Racine-Poon A, Howald H. Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects. Eur J Clin Pharmacol 1994;47:231-45.
7. Oparil S, Dyke S, Harris F, et al. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther 1996;18:797-810.
8. Black HR, Graff A, Shute D, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability, and safety compared to an angiotensin converting enzyme inhibitor lisinopril. J Hum Hypertens 1997;11:483-9.
9. Corea L, Cardoni O, Fogari R, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Clin Pharmacol Ther 1996;60:341-6.
10. Mallion J-M, Boutelant S, Chabaux P, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared to the angiotensin converting enzyme inhibitor enalapril. Blood Pressure Monogr 1999;2:179-185.
11. Hegner G, Fuast G, Freytag F, Meilenbrock S, Sullivan S, Bodin F. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared to hydrochlorothiazide. Eur J Pharmacol 1997;52:173-7.
12. Holwerda NJ, Fogari R, Angeli P, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypertens 1996;14:1147-51.
13. Bremner AD, Bauer M, Oddou-Stock P, Bodin F. Valsartan: long-term efficacy and tolerability compared with lisinopril in elderly patients with essential hypertension. Clin Exp Hypertens 1997;19: 1263-85.
14. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-52.